Sinobiopharma Reports Highlights From Audited Financial Results for the Fiscal Year Ended Ma... (curium Besylate has decreased to 2...)

Sinobiopharma Reports Highlights From Audited Financial Results for the Fiscal Year Ended May 31, 2009

Date:9/23/2009

curium Besylate has decreased to 29 percent of its price for the 12 months ended May 31, 2009, from 47 percent of its price for the 12 months ended May 31, 2008.

"The significant increases in sales revenue as well as gross and net profit -- achieved despite sustained economic turmoil and without any funds raised in the last fiscal year -- speak well to the growing success of Sinobiopharma's products in the marketplace and the Company's improved ability to produce and distribute them more cost-effectively," said Dr. Lequn Lee Huang, Sinobiopharma's President and CEO.

About Sinobiopharma

Sinobiopharma, Inc. is a fully integrated and highly innovative specialty biopharmaceutical company engaged in the research and development, manufacture and marketing of biopharmaceutical products in China, the world's fastest growing pharmaceutical market. Known as Dong Ying (Jiangsu) Pharmaceutical Co., Ltd. in China, the Company's current therapeutic focus is on anesthesia-assisted agents and cardiovascular drugs.

FORWARD LOOKING STATEMENTS

This news release may include "forward-looking statements" regarding Sinobiopharma, Inc., and its subsidiaries, business and project plans. Such forward looking statements are within the meaning of Section 27A of the Securities Act of 1933, as amended, and section 21E of the United States Securities and Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor created by such sections. Where Sinobiopharma, Inc. expresses or implies an expectation or belief as to future events or results, such expectation or belief is believed to have a reasonable basis. However, forward-looking statements are subject to risks, uncertainties and other factors, which could cause actual results to differ materially from future results expressed, projected or implied by such forward-looking statements. Sinobiopharma, Inc. d
'/>"/>

SOURCE Sinobiopharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related biology technology :

1. Emissary Capital Group Initiates Coverage on Sinobiopharma
2. Sinobiopharma Applies For Two Chinese Patents For Cisatracurium Besylate
3. Sinobiopharma Updates on Progress; Projects Increases in Sales and Revenues In 2009
4. Sinobiopharma Announces SFDA Approval of Anti-Hypertension Drug Perindopril
5. Sinobiopharma Secures Rights to Seven Key Patents
6. Sinobiopharma Reports a 141% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
7. Sinobiopharma Reports a 41% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
8. Sinobiopharma, Inc. Appoints New Director of Marketing
9. Sinobiopharma Signs Export Agreement With U.S. Pharmaceutical Supplier
10. Sinobiopharma Reports Financial Highlights for Six-Month Period Ending November 30, 2008
11. Economic Strength of Hawaii Seed Crop Industry Confirmed by Recent Reports

Post Your Comments:

(Date:12/14/2009)... 14 Vermillion, Inc. (Pink Sheets: ... William C. Wallen, Ph.D. Chief Scientific Officer, ... IDEXX Laboratories, will be joining its board ... plan. ,, "Bill brings more than ... diagnostics and biotechnology," said Gail Page, Vermillion ...

(Date:12/14/2009)... Mass., Dec. 14 Boston Scientific Corporation (NYSE: ... a public offering of $2 billion aggregate principal amount ... statement. The public offering consists of $850 million ... of 6.00 percent notes due January 2020 and $300 ... Boston Scientific plans to use the net proceeds for ...

(Date:12/14/2009)... delivery of Brookfield Engineering’s Powder Flow Tester – helping Brookfield ... smaller footprint and more compact design. , ... ... a US-based thermoforming company, has completed the delivery of Brookfield ... metal to a plastic enclosure with a smaller footprint and ...

(Date:12/11/2009)... Therapeutics, Inc., a biopharmaceutical company focused on improving ... cardiovascular and muscle disease, today announced the publication ... crucial role in the progression of amyotrophic lateral ... neuromuscular synaptic regeneration in mice. The findings, ... journal Science , reveal miR-206 as a ...

Breaking Biology Technology:Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors 2 Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors 3 Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors 4 Boston Scientific Announces Completion of $2 Billion Senior Notes Offering 2 Boston Scientific Announces Completion of $2 Billion Senior Notes Offering 3 Thermofab Helps Brookfield Engineering Move To A Compact Custom Plastic Enclosure 2 miRagen announces discovery of key microRNA implicated in Lou Gehrig's disease 2

[0] Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors [0] Boston Scientific Announces Completion of $2 Billion Senior Notes Offering [0] Thermofab Helps Brookfield Engineering Move To A Compact Custom Plastic Enclosure [0] miRagen announces discovery of key microRNA implicated in Lou Gehrig's disease

... March 5 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ... results for the fourth quarter and year ended December ... results in our Medical Products Business and were able ... initiatives despite a challenging year for TAXUS," said Dr. ...

... appealed, delisting scheduled for March 12, 2009 NEW YORK, ... KERX ) today announced that it received a letter ... that the Company had failed to regain compliance with ... have a minimum of $2,500,000 in stockholders, equity, or ...

... Inc., announced today that it has successfully completed a ... Capital on behalf of the MPM Bio IV NVS ... of a Phase 1/2 human clinical study of its ... disease undergoing surgery for arteriovenous fistula (AVF) creation. Additionally, ...

Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 Keryx Biopharmaceuticals Inc. Announces Receipt of Nasdaq Delisting Notification Proteon Therapeutics Completes $38M Equity Financing; Initiates Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients and Signs Option Agreement With Major Pharmaceutical Company

(Date:12/11/2009)... , Montreal, December 11, 2009 Canadian ... cancer. In the December 11 edition of the prestigious ... de Montral and the Universit de Sherbrooke explain how ... activity of cytokines, hormones that are culprits in cancer-prone ... people exposed to asbestos. , "Excessive cytokine activity ...

(Date:12/11/2009)... CORVALIS, ORFruit growers, profits have traditionally been ... climates where growing seasons can be short. ... developed varieties are being introduced that offer ... the offseasonresulting in economic bonuses for both ... new varieties of blackberry called "primocane-fruiting", which ...

(Date:12/11/2009)... roe of hake, lumpsucker and salmon is the best dietary ... by researchers at the University of Almera (UAL). The scientists ... found all of these contained high levels of these fatty ... now there had been no precise understanding of the nutritional ... of researchers from the UAL has now shown that this ...

Breaking Biology News(10 mins):Scientists identify natural anti-cancer defenses 2 New management methods extend blackberry season 2 Roe of marine animals is best natural source of omega-3 2 DaVita com Provides Easy Recipes to Plan Your Fathers Day Dinner 49539 1 DaVita com Provides Easy Recipes to Plan Your Fathers Day Dinner 49539 2 DaVita com Provides Easy Recipes to Plan Your Fathers Day Dinner 49539 3 Last Day of Special Olympics Minnesotas 2009 Summer Games 49537 1 Last Day of Special Olympics Minnesotas 2009 Summer Games 49537 2 Last Day of Special Olympics Minnesotas 2009 Summer Games 49537 3 RSA Designated as the Leader in One Time Password Market by Frost 26 Sullivan 8936 1 RSA Designated as the Leader in One Time Password Market by Frost 26 Sullivan 8936 2 RSA Designated as the Leader in One Time Password Market by Frost 26 Sullivan 8936 3 RSA Designated as the Leader in One Time Password Market by Frost 26 Sullivan 8936 4

[0] Scientists identify natural anti-cancer defenses [1] New management methods extend blackberry season [0] Roe of marine animals is best natural source of omega-3

... reduce age-related macular degeneration ,(AMD) which is the major cause ... the third cause of global blindness, according to,a study published ... , There are two types of AMD, wet and dry. ... loss. A team of researchers across seven European,countries and co-ordinated ...

... in the western U.S., the New Zealand mud snail currently ... into rivers and tributaries, according to a Penn State team ... but are not good fish food replacements for the native ... the shell," says Edward P. Levri, associate professor of biology ...

... Arctic Ocean warms this century, shellfish, snails and other ... of the northern Atlantic that was interrupted by cooling ... of geology at the University of California, Davis, and ... Climate models predict a nearly ice-free Arctic Ocean by ...

Other Biology News:Eat oily fish at least once a week to protect your eyesight in old age 2 Tiny invasive snail impacts Great Lakes, alters ecology 2 Tiny invasive snail impacts Great Lakes, alters ecology 3 Pacific shellfish ready to invade Atlantic 2

Eat oily fish at least once a week to protect your eyesight in old age Tiny invasive snail impacts Great Lakes, alters ecology Pacific shellfish ready to invade Atlantic

Mouse GM CSF Construction Kit provides antigen affinity purified polyclonal capture and tracer antibodies, and antigen standard for development of approximately ten microplate assays....

... GeneBLAzer cell-based assays utilize the ... of the negatively charged fluorescent beta-lactamase ... esters readily enter the cell, where ... converts them into their negatively charged ...

Inquire...

Homogenizing Solution, 18ml Proteinase K - [50ug/l] 75 l...

Biology Products:

Mouse GM CSF ELISA construction Kit from Antigenix America Inc.CCF4-AM from Invitrogen Collar for Vac-Man^® 96 Vacuum Manifold from Promega QuantiGene Plex Reagent Set for Animal/Plant Tissue from Panomics

Sinobiopharma Reports Highlights From Audited Financial Results for the Fiscal Year Ended Ma...(curium Besylate has decreased to 2...)